98%
921
2 minutes
20
In the presence of room reverberation and background noise, the performance of frame-level speaker localization is severely limited. To address this challenge, this study performs multi-channel speech enhancement based on complex spectral mapping (CSM), followed by direction-of-arrival (DOA) estimation using weighted generalized cross-correlation with phase transform (GCC-PHAT). The proposed approach differs from prevailing deep learning methods that operate on multi-channel inputs directly for speaker localization. This study initially investigates multi-input single-output (MISO) based speech enhancement models with two loss functions and then extends to multi-input multi-output (MIMO) based modeling for conceptual and computational efficiency. The results demonstrate that the phase estimates obtained from CSM models are reliable for frame-level DOA estimation and MIMO systems outperform MISO systems. In addition, the study proposes new multi-channel loss functions for MIMO systems that incorporate phase differences in order to better preserve inter-channel phase relations, which is key to accurate sound localization. Systematic evaluations with multiple microphone array geometries using both simulated and recorded room impulse responses, as well as real recordings, demonstrate that the proposed model yields excellent frame-level speaker localization results in reverberant and noisy environments and outperforms related methods by a large margin, even surpassing their utterance-level results.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1121/10.0038627 | DOI Listing |
Diabetes Ther
September 2025
Department of Diabetes and Endocrinology, Guy's and St Thomas' NHS Trust, London, UK.
Introduction: This post hoc analysis of an A Toujeo Observational Study (ATOS) aims to evaluate the real-world effectiveness and safety of insulin glargine 300 U/ml (Gla-300) in high-risk subgroups of insulin-naïve people with type 2 diabetes (PwT2D) from multiple geographical regions (Asia, the Middle East, North Africa, Latin America, and Eastern Europe).
Methods: In these post hoc analyses of ATOS, a real-world, 12-month, prospective study included 4422 insulin-naïve adults (age ≥ 18 years) with type 2 diabetes (T2D) uncontrolled (HbA > 7% and ≤ 11%) on one or more oral antidiabetic drugs (OADs) who initiated Gla-300 treatment as per routine practice. Primary and secondary endpoints were studied according to renal impairment (RI) status (without or with) and age group (≥ 70 years).
Clin Neurol Neurosurg
September 2025
Neurovascular Research Unit, Department of Neurology, Copenhagen, University Hospital - Herlev and Gentofte, Herlev, Denmark; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark; Department of Brain, and Spinal Cord Injury, Copenhagen University Hospital - Rigshospitalet,
Objective: Severity and outcome of stroke may be associated with a concomitant or subsequent inflammatory response. C-reactive protein (CRP) may correlate with length of stay (LOS) in hospital, indicating increased complexity of stroke patients with an ongoing inflammatory reaction upon admission.
Methods: This retrospective cross-sectional study used data from admissions to the non-comprehensive Stroke Unit, which receives patients ineligible for revascularization therapy at Herlev-Gentofte hospital, in 2019 and 2020.
J Neurooncol
September 2025
Department of Radiation Oncology, Stanford University, Stanford, CA, USA.
Purpose: We report outcomes of repeat stereotactic radiosurgery (rSRS) to sites of tumor progression following initial SRS. Additionally, we sought to determine if, at the time of recurrence following initial SRS, surgical resection of the tumor followed by SRS (surgery + rSRS) provided benefit compared to rSRS alone.
Methods: We retrospectively reviewed patients treated with rSRS for local recurrence after initial SRS.
Mol Diagn Ther
September 2025
Division of Pathology, IEO, European Institute of Oncology IRCCS, Via G. Ripamonti 435, 20141, Milan, Italy.
Background And Objective: Sacituzumab govitecan, an anti-trophoblast cell surface antigen 2 (TROP2) antibody-drug conjugate, has been approved by both the US Food and Drug Administration and European Medicines Agency for patients with metastatic triple-negative breast cancer who have received two or more prior systemic therapies, including at least one of them for advanced disease. Although TROP2 evaluation is not required for patient selection, survival data from the ASCENT trial show improved response rates in patients with high TROP2 expression by immunohistochemistry. However, there is no standardized testing assay for these patients.
View Article and Find Full Text PDFHeart Lung Circ
September 2025
Lifelong Health Theme, South Australian Health and Medical Research Institute, Adelaide, SA, Australia; Adelaide Medical School, Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, SA, Australia; Department of Cardiology, Central Adelaide Local Health Network, Adelaide, SA,
Cardiovascular-kidney-metabolic (CKM) syndrome is a term that is increasingly used to describe interconnected conditions that lead to poor health outcomes, including cardiovascular disease, chronic kidney disease, type 2 diabetes, and obesity. Historically, there have been very few targeted pharmacotherapies available that have changed cardiovascular outcomes for people with CKM syndromes; however, over the past decade, new pharmacologic options have rapidly expanded, with strong evidence for cardiovascular and kidney protective benefits in CKM conditions. Of note, sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists have emerged as key therapeutic options and are now widely guideline-endorsed.
View Article and Find Full Text PDF